We compared TMB level in different subgroups of NSCLC and investigated the impact of TMB on the efficacy of EGFR–tyrosine kinase inhibitor (TKI) or pemetrexed/platinum in advanced NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.